COMMUNIQUÉS West-GlobeNewswire

Xtant Medical Postpones Release of Third Quarter 2017 Financial Results

09/11/2017 - 13:30

BELGRADE, Mont., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, announced that it has postponed [...]

Avenue Therapeutics Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights

09/11/2017 - 13:30

NEW YORK, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI ) (“Avenue”), a Fortress Biotech (NASDAQ: FBIO ) Company, today announced financial results and recent corporate highlights for the [...]

Merus to Present at the Jefferies London Healthcare Conference

09/11/2017 - 13:30

UTRECHT, The Netherlands, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ: MRUS ), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton [...]

Idera Pharmaceuticals Presents Positive Translational and Clinical Data Update from Ongoing IMO-2125 Development Program at the 2017 Society for Immunotherapy of Cancer Annual Meeting (SITC)

09/11/2017 - 13:30

- Available Translational Data Continue to Demonstrate Correlation between Proliferation and Clonal Expansion of T-Cells to Clinical Responses - - An additional 5th Unconfirmed RECIST v1.1 Response Observed in 10th [...]

Meridian Bioscience Reports Fourth Quarter and Full-Year Operating Results, Declares Regular Fourth Quarter Cash Dividend, Sets Fiscal 2018 Cash Dividend Rate, and Reaffirms Fiscal 2018 Guidance

09/11/2017 - 13:30

GENERAL HIGHLIGHTS CINCINNATI, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO ) today: reported fourth quarter and full-year fiscal 2017 net revenues of $49.7 million and $200.8 million, [...]

Interpace Diagnostics to Host Conference Call and Webcast to Discuss Third Quarter 2017 Financial Results and Business Progress on Monday November 13, 2017

09/11/2017 - 13:30

PARSIPPANY, N.J., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG ) (“Interpace” or “the Company”), a fully integrated commercial company that provides clinically useful molecular [...]

Cancer Genetics Reports Record Third Quarter 2017 Revenue and 134% Increase in Contracted Bookings from Major Biotech and Pharmaceutical Companies

09/11/2017 - 13:22

Actively Working with 9 of Top 10 Biopharma Companies Globally Revenue Increased 19% to $8.0 Million, Gross Margin Improved to 43% Conference call at 8:30 a.m. EST, Thursday, November 9, 2017 RUTHERFORD, N.J., Nov. 09, [...]

Alliqua BioMedical, Inc. Reports Third Quarter of Fiscal Year 2017 Financial Results and Increases Fiscal Year 2017 Financial Outlook

09/11/2017 - 13:02

YARDLEY, Pa., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Alliqua BioMedical, Inc. (Nasdaq: ALQA ) ("Alliqua" or "the Company"), a regenerative technologies company committed to restoring tissue and rebuilding lives, today [...]

Alliqua BioMedical, Inc. Engages Cowen to Assist in Evaluating Potential Strategic Alternatives

09/11/2017 - 13:01

YARDLEY, Pa., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Alliqua BioMedical, Inc. (Nasdaq: ALQA ) ("Alliqua" or "the Company"), a regenerative technologies company committed to restoring tissue and rebuilding lives, today [...]

Summit Highlights Utrophin Modulation as a Potential Universal Treatment Option in DMD at Action Duchenne

09/11/2017 - 13:00

Summit Therapeutics plc ("Summit" or the "Company") SUMMIT HIGHLIGHTS UTROPHIN MODULATION AS A POTENTIAL UNIVERSAL TREATMENT OPTION IN DMD AT 15th ACTION DUCHENNE INTERNATIONAL CONFERENCE New Preclinical Data Show [...]

Sanofi, Principia agree to develop multiple sclerosis drug candidate

09/11/2017 - 13:00

Sanofi, Principia agree to develop multiple sclerosis drug candidate Clinical-stage oral drug candidate (PRN2246) with the potential to treat multiple sclerosis Principia to receive $40 million upfront payment, future [...]

Accord entre Sanofi et Principia pour le développement d'un candidat-médicament contre la sclérose en plaques

09/11/2017 - 13:00

Accord entre Sanofi et Principia pour le développement d'un candidat-médicament contre la sclérose en plaques L'accord porte sur un candidat-médicament par voie orale au stade du développement clinique (PRN2246) dans le [...]

2017 HomeCare Elite Recognizes Top Amedisys Care Centers Nationwide

09/11/2017 - 13:00

BATON ROUGE, La., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Amedisys (NASDAQ: AMED ), a leading healthcare at home company, today announced that 48 percent of its home health care centers across the country have been named to [...]

Natus to Present at 29th Annual Piper Jaffray Healthcare Conference

09/11/2017 - 13:00

PLEASANTON, Calif., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: BABY ) today announced that Jonathan Kennedy, Executive Vice President and Chief Financial Officer, will present at the 29 th [...]

Athenex, Inc. Announces Third Quarter 2017 Results

09/11/2017 - 13:00

Encouraging results of 1 st interim analysis of the Oraxol Phase III clinical trial for breast cancer Commencement of the KX-01 ointment Phase III clinical trials for Actinic Keratosis Launched Oxaliplatin Injection, [...]

ContraFect Announces Third Quarter 2017 Financial Results

09/11/2017 - 13:00

YONKERS, N.Y., Nov. 09, 2017 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ: CFRX ), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug- [...]

Codexis to Present at Two Investment Conferences in November

09/11/2017 - 13:00

REDWOOD CITY, Calif., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS ), a leading protein engineering company, announces that management will present at two investment conferences in November: 8th Annual [...]

Nabriva Therapeutics Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights

09/11/2017 - 13:00

- Positive topline results from pivotal LEAP 1 trial announced in September, with read-out from second Phase 3 trial, LEAP 2, expected in the spring of 2018 - - $112.7 million cash and investments as of September 30, [...]

BeyondSpring Reports Third Quarter 2017 Operational and Financial Results

09/11/2017 - 13:00

NEW YORK, Nov. 09, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI ) (“BeyondSpring” or the “Company”), a late-stage clinical biopharmaceutical company focusing on the development of a pipeline of innovative [...]